NKGen Biotech, Inc.

NKGen Biotech, Inc., trading under the ticker GFOR, reached public markets through its business combination with Graf Acquisition Corp. IV, a blank-check company sponsored by Graf Holdings that completed its IPO in 2021. The combined company operates in the clinical-stage biopharmaceutical sector, with a pipeline centered on natural killer cell-based immunotherapies targeting neurodegenerative diseases and oncology indications. On August 30, 2024, NKGen Biotech filed an 8-K current report with the Securities and Exchange Commission under accession number 0001213900-24-074140. To access the full filing record, sponsor history, and real-time SPAC intelligence on GFOR and thousands of other transactions, sign up for complete data on SpacDesk.